BioXyTran, Inc. is a biopharmaceutical company founded with the mission to develop innovative anti-necrosis drugs aimed at treating ischemia and preventing catastrophic brain damage following strokes. The company's core vision revolves around leveraging novel glycan-based platform technology, known as glycovirology, to create carbohydrate drugs that act as entry inhibitors targeting viruses directly. BioXyTran focuses on addressing degenerative diseases and serves patients primarily in the United States.

Notable figures affiliated with BioXyTran include key scientists and industry experts who have contributed significantly to the development of their proprietary technologies. The company has garnered attention from investors interested in groundbreaking medical treatments. BioXyTran's achievements include advancing its main drug candidate through various stages of development, showcasing its potential impact on treating ischemia and stroke-related conditions. The company's innovative approach has positioned it as a promising player in the biopharmaceutical industry, aiming to make a substantial impact on patient health outcomes.